PSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration-resistant prostate cancer: the non-interventional QoLiTime study
Crossref DOI link: https://doi.org/10.1007/s00345-017-2138-x
Published Online: 2018-01-05
Published Print: 2018-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hammerer, Peter
Al-Batran, Salah-Eddin
Windemuth-Kieselbach, Christine
Keller, Martin
Hofheinz, Ralf-Dieter
Funding for this research was provided by:
Sanofi
License valid from 2018-01-05